中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

已收盘 07-29 16:08:21

5.230

+0.140

+2.75%

最高5.240	最低5.040	成交量6,415万
今开5.150	昨收5.090	日振幅3.93%
总市值977.12亿	流通市值977.12亿	总股本186.83亿
成交额3.31亿	换手率0.34%	流通股本186.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5.23,"timestamp":1785312501000,"preClose":5.09,"halted":0,"volume":64146085,"delay":0,"changeRate":0.02750491159135571,"floatShares":18683000000,"shares":18683000000,"eps":0.15034115926524338,"marketStatus":"已收盘","change":0.14,"latestTime":"07-29 16:08:21","open":5.15,"high":5.24,"low":5.04,"amount":331056230,"amplitude":0.039293,"askPrice":5.23,"askSize":415000,"bidPrice":5.22,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":0.15034115926524338,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785375000000},"marketStatusCode":5,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.09,"dividendRate":0.019881,"openAndCloseTimeList":[[1785288600000,1785297600000],[1785301200000,1785312000000]],"volumeRatio":1.004611,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.5231,"impliedVolPercentile":0.7469},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2655832649","title":"【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655832649?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:21","pubTimestamp":1785288070,"startTime":"0","endTime":"0","summary":"国内外的多肽CDMO公司均加大对于产能的投资建设，尤其注重从临床前到商业化生产的一站式服务能力建设。2026年4月，凯莱英医药与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986985","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","BK1564","01801","01177","LU1328277881.USD","LU1719994722.HKD","HK0000165453.HKD","LU0634319403.HKD","LU2242644610.SGD","IE00B5MMRT66.SGD","01877","LU1720050803.USD","06185","06160","LU0052750758.USD","LU0979878070.USD","LU0359202008.SGD","LU0051755006.USD","LU0417516738.SGD","BK1141","BK1588","09995","02616","IE00B0JY6N72.USD","BK1574","SG9999002463.SGD","LU1008478684.HKD","02611","IE00B543WZ88.USD","02142","601211","LU2476274308.USD","LU0307460666.USD","LU0561508036.HKD","BK1147","LU0181495838.USD","CDMO","161027","01093","LU0588546209.SGD","LU1251922891.USD","BK1583","02269","LU0348784397.USD","09688","09926","BK1610","LU0067412154.USD","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","06996","LU0856984785.SGD","06990","03329","09926","LU0572944931.SGD","02096","02269","01801","LU2476274308.USD","LU2399975544.HKD","LU1880383366.USD","01177","03692","09996","LU1813983027.USD","159938","01951","01548","LU2097828714.EUR","02162","09939","KCE","02273","HK0000320223.HKD","BK1219","LU2328871848.SGD","BK1587","LU0417516571.SGD","09966","01530","00013","06160","KURE","LU0634319403.HKD","LU2039709279.SGD","03759","01093","BK1521","LU0588546209.SGD","06078","HK0000165453.HKD","LU0196878994.USD","LU0348783233.USD","LU1720050803.USD","02268","02596","01952","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654601684","title":"中国生物制药与印尼Tempo Scan组合营","url":"https://stock-news.laohu8.com/highlight/detail?id=2654601684","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654601684?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:34","pubTimestamp":1785144865,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1521","HK0000165453.HKD","BK1191","IE00BZ08YS42.EUR","01177","BK1589","IE00BZ08YT58.USD","BK1515","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198968853","title":"中国生物制药(01177)携手Tempo Scan设立印尼合资公司 持股51%","url":"https://stock-news.laohu8.com/highlight/detail?id=1198968853","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198968853?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:52","pubTimestamp":1785142334,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司（01177，简称“中国生物制药”）7月27日公告称，已与PT Tempo Scan Pacific Tbk（“Tempo Scan”）签署合资协议，共同成立PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA（“TCBI”）。根据协议，中国生物制药持有TCBI 51%股权，Tempo Scan持有49%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654013305","title":"中国生物制药(01177)与Tempo Scan成立战略合资企业 进一步提升印尼创新药物可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=2654013305","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654013305?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:39","pubTimestamp":1785141563,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告， 团已与PT Tempo Scan Pacific Tbk签署合资协议，共同成立PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA。根据协议，集团持有TCBI 51%的股权，Tempo Scan持有49%。TCBI将深度融合Tempo Scan深耕印尼市场的本地化经验与集团在创新研发及产品管线方面的核心优势，聚焦于药品注册、临床开发、医学事务、市场准入及全品类药品的商业化，并适时评估未来在印尼开展本地化生产的可行性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","HK0000165453.HKD","BK1161","IE00BZ08YT58.USD","MEDX","BK1574","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","06978","01177","BK1515","BK1521","IBBQ","159992","BK1589","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129465488","title":"中国生物制药合资项目：聚焦印尼监管、临床、商业化及本地化生产","url":"https://stock-news.laohu8.com/highlight/detail?id=1129465488","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129465488?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:37","pubTimestamp":1785141429,"startTime":"0","endTime":"0","summary":"中国生物制药（SBP GROUP）宣布，一项合资计划将围绕监管事务、临床试验、商业化布局以及印尼本地制造环节展开。这一战略举措，旨在深化其东南亚市场渗透。通过整合监管对接、临床推进、商业推广与本地化生产四大核心领域，合资企业有望提升区域运营效率。此举不仅彰显了企业拓展国际版图的决心，更凸显了其对印尼医药市场潜力的精准把握。从监管审批到产品落地，从临床研究到市场销售，再到生产环节的本土化，全链条布局正在形成。这是一次系统性的资源配置，而非单一环节的突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","IE00BZ08YR35.GBP","01177","BK1515","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1521","BK1191","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100064830","title":"中国生物制药与Tempo Scan携手，共设印尼合资公司PT Tempo Cttq Biopharmaceutical Indonesia","url":"https://stock-news.laohu8.com/highlight/detail?id=1100064830","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100064830?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:37","pubTimestamp":1785141429,"startTime":"0","endTime":"0","summary":"中国生物制药（SBP GROUP）迈出重要一步，与Tempo Scan达成合作，共同组建一家合资企业。这家新公司名为PT Tempo Cttq Biopharmaceutical Indonesia，标志着双方在印尼市场的战略布局正式落地。通过这一合作，中国生物制药旨在拓展其国际业务版图，并借助Tempo Scan的本地经验，进一步深耕东南亚医药领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1589","BK1521","BK1515","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01177","IE00BZ08YT58.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654535092","title":"大行评级丨野村：下调中国生物制药目标价至8.26港元，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2654535092","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654535092?lang=zh_cn&edition=full","pubTime":"2026-07-27 14:29","pubTimestamp":1785133786,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BZ08YT58.USD","IE00BZ08YS42.EUR","BK1191","HK0000165453.HKD","BK1515","BK1589","BK1521","IE00BZ08YR35.GBP","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194736042","title":"中国生物制药（01177）旗下创新药IM-101获NMPA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1194736042","media":"公告速递","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194736042?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:46","pubTimestamp":1784799988,"startTime":"0","endTime":"0","summary":"2026年7月23日，中国生物制药公告称，其附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药IM-101注射液「PreS1重组融合蛋白」已获中国国家药品监督管理局临床试验批准，拟用于治疗慢性乙型肝炎。\\n\\n全球约有2.9亿慢性HBV感染者，其中中国约占7,500万例。\\n\\n公司表示，IM-101的获批将进一步丰富其在主动免疫治疗领域的产品组合，未来将持续探索单药及联合治疗方案，为肝病患者提供更多元化的治疗选择。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186147355","title":"中国生物制药IM-101注射液获NMPA批准开展慢性乙型肝炎临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1186147355","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186147355?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:45","pubTimestamp":1784799939,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，其创新药物IM-101注射液已获得中国国家药品监督管理局的临床试验批准，将针对慢性乙型肝炎适应症展开临床研究。这一进展标志着公司在肝病治疗领域的研发管线取得重要突破，有望为慢性乙肝患者提供新的潜在治疗选择。公司表示，将严格按照相关法规要求，尽快推进该药物的临床开发工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","HK0000165453.HKD","BK1515","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1521","BK1191","01177","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108496261","title":"异动解读｜中国生物制药盘中下跌3.18%，报5.19港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108496261","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108496261?lang=zh_cn&edition=full","pubTime":"2026-07-23 15:44","pubTimestamp":1784792643,"startTime":"0","endTime":"0","summary":"7月23日，中国生物制药盘中下跌3.18%，报5.19港元/股，成交额2.24亿港元。中国生物制药所在的制药行业中，板块表现分化，个股中，翰森制药跌1.03%，石药集团跌0.71%，恒瑞医药涨0.43%，欧康维视生物-B跌3.53%，康哲药业涨0.9%。中国生物制药有限公司是一家主要从事制药业务的投资控股公司，通过中药现代制剂及西药、投资、其他三个分部运营，主要从事生产、销售及配销中药现代制剂及西药产品业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读｜中国生物制药盘中下跌3.18%，报5.19港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196761276","title":"异动解读｜中国生物制药盘中上涨3.13%，制药板块回暖叠加近期多重利好延续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1196761276","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196761276?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:50","pubTimestamp":1784685046,"startTime":"0","endTime":"0","summary":"7月22日，中国生物制药盘中上涨3.13%，报5.23港元/股，成交额9271.52万港元，在前一交易日下跌3.09%后快速反弹。消息面上，制药板块今日整体回暖，石药集团涨0.24%，翰森制药涨1.9%，恒瑞医药涨1.68%。公司近期利好持续发酵：7月14日旗下TRD205获CDE突破性治疗药物认定；7月10日IDH1抑制剂TQB3454上市申请获受理；7月8日与阿斯利康达成TQC3721海外独家授权协议，总对价最高达19亿美元，同日深化与GSK呼吸领域战略合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159325472","title":"异动解读｜中国生物制药盘中下跌3.09%，报5.01港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159325472","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159325472?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:59","pubTimestamp":1784602783,"startTime":"0","endTime":"0","summary":"7月21日，中国生物制药盘中下跌3.09%，报5.01港元/股，成交额1.38亿港元。中国生物制药所在的制药行业中，板块整体承压，个股中，石药集团跌2.59%，翰森制药跌3.21%，恒瑞医药跌4.26%，先声药业跌0.08%，凯莱英涨0.25%。中国生物制药有限公司是一家主要从事制药业务的投资控股公司，通过中药现代制剂及西药、投资、其他三个分部运营，主要从事生产、销售及配销中药现代制剂及西药产品业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134758180","title":"异动解读｜中国生物制药盘中上涨3.01%，制药板块集体反弹叠加近期多重利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1134758180","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134758180?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:06","pubTimestamp":1784513201,"startTime":"0","endTime":"0","summary":"7月20日，中国生物制药盘中上涨3.01%，报5.14港元/股，成交额6755.82万港元。制药板块集体走强，东阳光药涨5.29%，石药集团涨4.32%，恒瑞医药涨4.18%，凯莱英涨4.1%，翰森制药涨3.71%。公司近期利好密集：7月14日旗下TRD205获CDE突破性治疗药物认定；7月10日IDH1抑制剂TQB3454上市申请获受理；7月8日与阿斯利康达成TQC3721海外独家授权协议，总对价最高达19亿美元，同日深化与GSK呼吸领域战略合作。多家券商维持买入评级，招银国际目标价8.70港元，交银国际目标价7.70港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126626148","title":"异动解读｜中国生物制药盘中下跌3.04%，报4.99港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126626148","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126626148?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:02","pubTimestamp":1784253745,"startTime":"0","endTime":"0","summary":"7月17日，中国生物制药盘中下跌3.04%，报4.99港元/股，成交额1.63亿港元。中国生物制药所在的制药行业中，板块整体承压，个股中，石药集团跌3.72%，翰森制药跌3.14%，恒瑞医药跌3.62%，凯莱英跌8.16%，绿叶制药跌4.05%。中国生物制药有限公司是一家主要从事制药业务的投资控股公司，通过中药现代制剂及西药、投资、其他三个分部运营，主要从事生产、销售及配销中药现代制剂及西药产品业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651810439","title":"港股早盘高开高走 恒指半日涨1.46% 创新药、猪肉概念强势","url":"https://stock-news.laohu8.com/highlight/detail?id=2651810439","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651810439?lang=zh_cn&edition=full","pubTime":"2026-07-15 12:11","pubTimestamp":1784088667,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘高开高走，三大股指均升逾1%。截至午间收盘，恒生指数上涨1.46%；国企指数涨1.16%；恒生科技指数涨1.39%。猪价底部大概率已现，预计周期临近上行。预计2026年半年度归属于上市公司股东的扣除非经常性损益的净利润约为人民币20.00亿元到人民币26.00亿元，与上年同期相比，将增加人民币18.62亿元到人民币24.62亿元，同比增长1349%到1784%。MiniMax盘中反复拉升，午间收涨14.96%。港股将受益于中国内地强劲而有韧性的经济表现，建议超配H股。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985921","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1523","LU0251144936.SGD","LU0588546209.SGD","LU1808992512.USD","SG9999002562.SGD","LU0463099449.HKD","BK1550","83115","LU0828237940.HKD","LU0862451753.SGD","02714","LU0405327494.USD","LU0348766576.USD","BK1549","BK1562","IE0008369823.USD","LU0862451837.USD","LU3063872942.SGD","HSTECH","00857","LU0516422952.EUR","01477","LU0417516902.SGD","LU0821914370.USD","LU1813983027.USD","LU2399975544.HKD","LU1048588211.SGD","BK1226","LU1226287792.SGD","BK1528","03115","LU2476274308.USD","BK1515","LU2045819591.USD","IE00B031HY20.USD","01610","LU1008478684.HKD","LU2097828805.USD","LU0348735423.USD","SGXZ86797644.SGD","SG9999001226.SGD","WXXWY","LU1226287529.USD","LU1880383366.USD","SG9999012744.USD","06869","MCHmain","LU0880133367.SGD","IE00BWDBJ730.SGD","LU1785774172.SGD","LU0359202008.SGD","LU0455707207.USD","LU0163747925.USD","LU0348767384.USD","LU1051769294.HKD","LU1226288170.HKD","BK1589","LU0315178854.USD","LU1303224171.USD","LU0173614495.USD","LU0588545490.SGD","LU1497733631.SGD","LU0890818403.SGD","LU1522347837.USD","LU0228367735.SGD","03037","BK1610","LU1831875114.USD","LU0051755006.USD","LU0348805143.USD","LU1960683339.HKD","SG9999001093.SGD","LU0634319403.HKD","LU0823426308.USD","LU0417516571.SGD","LU0651946864.USD","BK1584","LU0043850808.USD","LU0865486749.SGD","IE0008368742.USD","BK1521","LU1515016050.SGD","BK1603","LU0320764599.SGD","LU1224444064.USD","BK1607","BK1191","BK1161","LU0348825331.USD","KURE","LU1046422090.SGD","IE00B5MMRT66.SGD","LU0588545730.USD","LU0359201885.HKD","IE00B543WZ88.USD","LU2039709279.SGD","LU1051768304.USD","BK1574","LU0348783662.USD","BK1614","LU0244354667.USD","LU0441854154.USD","LU0708995583.HKD","SG9999002463.SGD","IE00BPRC5H50.USD","LU0456846285.SGD","LU1770034418.SGD","SG9999003461.SGD","HK0000286598.CNH","LU2257852520.SGD","LU1720050803.USD","LU0169518387.USD","LU0501845795.SGD","82800","LU0502904849.HKD","LU0588545904.SGD","LU0067412154.USD","LU0072913022.USD","601869","LU1794554557.SGD","09926","IE00BQJZWZ67.USD","LU1282651121.HKD","02359","02419","LU1807302812.USD","LU2097828714.EUR","07500","LU0871576103.HKD","LU1242518857.USD","LU0572944931.SGD","LU2097828474.EUR","LU0611395673.USD","LU1719994722.HKD","002714","LU1675838814.USD","IE00BZ08YR35.GBP","LU0456827905.SGD","LU1226288253.USD","603259","HK0000165453.HKD","LU0640798160.USD","09115","IE00BZ08YT58.USD","LU1634259557.SGD","LU2125910500.SGD","688981","LU1497734951.SGD","LU0675040207.SGD","07300","601628","BK1117","HSI","SCHYY","SGXZ62798434.SGD","LU0417516738.SGD","513600","LU1152091168.USD","01801","BK1506","LU0164865239.USD","00100","LU0315179316.USD","IE00B19Z5X02.USD","LU0819121731.USD","LU1115378108.SGD","LU0314109678.HKD","SBHMY","SG9999012736.USD","LU1188198961.HKD","LU0540923850.HKD","SG9999006597.SGD","LU0469268626.HKD","BK1141","LU0516422366.SGD","LU1211504680.USD","LU2778985437.USD","01177","07200","LU0140636845.USD","LU1242518931.SGD","SG9999004220.SGD","SG9999012728.SGD","02269","601857","LU0359201612.USD","LU0405327148.USD","LU0052750758.USD","LU1634259391.SGD","LU0516423174.USD","BK1172","01928","LU0516423091.SGD","LU0326950275.SGD","LU2097828631.EUR","BK1184","BK1149","LU1023057109.AUD","BK1163","BK1237","BK1583","02833","LU1226287875.USD","LU1251922891.USD","LU2097828557.USD","LU0348827113.USD","LU0516422440.USD","LU2488822045.USD","IE00B0JY6N72.USD","LU0972618739.USD","LU0348784397.USD","LU0561508036.HKD","LU2293587155.HKD","LU0856984785.SGD","LU0307460666.USD","LU2476274720.SGD","LU1961090484.USD","LU0039217434.USD","00981","02268","00386","LU0651947912.USD","LU1328277881.USD","02628","LU0531971595.HKD","LU0823426480.USD","02800","IE0032431581.USD","LU0327786744.USD","LU2242644610.SGD","LU0211977185.USD","01093","LU1048596156.SGD","600028","LU1969619763.USD","LU1993786604.SGD","03419","LU1497733557.USD","SG9999012710.SGD","SG9999014674.SGD","LU0181495838.USD","LU2328871848.SGD","BK1526","IE00BZ08YS42.EUR","LU0293314216.USD","LU1951186391.HKD","LU0048597586.USD","LU0348783233.USD","06990","LU1688375341.USD","LU0979878070.USD","HHImain","BK1576","LU0072462343.USD","LU1152091754.HKD","LU0196878994.USD","LU0287142896.SGD","LU1282651048.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651369804","title":"港股异动 | 中国生物制药(01177.HK)涨超6% TRD205“AT2R拮抗剂”已被CDE纳入突破性治疗药物名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2651369804","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651369804?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:33","pubTimestamp":1784086389,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","IE00BZ08YT58.USD","HK0000165453.HKD","BK1521","BK1191","IE00BZ08YS42.EUR","BK1515","01177","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181463889","title":"异动解读｜中国生物制药盘中上涨3.72%，TRD205获CDE突破性治疗药物认定叠加大摩上调盈测","url":"https://stock-news.laohu8.com/highlight/detail?id=1181463889","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181463889?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:54","pubTimestamp":1784080491,"startTime":"0","endTime":"0","summary":"7月15日，中国生物制药盘中上涨3.72%，报5.3港元，成交额1.06亿港元。消息面上，公司7月14日公告，旗下北京泰德制药自主研发的1类新药TRD205已完成针对慢性术后神经病理性疼痛的II期临床试验，凭借积极数据获CDE纳入突破性治疗药物名单。该药仅作用于外周，有望避免中枢神经系统类药物常见不良反应，且目前临床尚无针对CPSNP的专用治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175798657","title":"中国生物制药（01177）TRD205获纳入CDE突破性治疗药物名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1175798657","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175798657?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:31","pubTimestamp":1784025089,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司7月14日公告，旗下子公司北京泰德制药股份有限公司自主研发的国家1类新药TRD205已完成针对慢性术后神经病理性疼痛的Ⅱ期临床试验，并凭借积极数据被国家药品监督管理局药品审评中心纳入“突破性治疗药物”名单。由于仅作用于外周，该药物有望避免中枢神经系统类药物常见的不良反应。目前临床尚无针对CPSNP的专用治疗药物，现有方案疗效及耐受性均存在局限。公告日期为2026年7月14日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134690574","title":"中国生物制药旗下TRD205获药审中心授予突破性疗法认定，II期临床试验用于CPSNP展现积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1134690574","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134690574?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:29","pubTimestamp":1784024960,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，其创新药物TRD205在针对慢性疼痛性周围神经病变（CPSNP）的II期临床试验取得积极进展后，已获得中国国家药品监督管理局药品审评中心授予的突破性疗法认定。\n这一认定标志着该药物在解决未满足的临床需求方面获得了监管机构的高度认可，有望加速其后续的临床开发和上市审评进程。TRD205作为一种新型治疗选择，其II期试验数据展现了在缓解CPSNP患者疼痛症状方面的潜力。\n突破性疗法认定旨在鼓励针对严重危及生命或影响生活质量的疾病、且尚无有效治疗手段或具有明显临床优势的创新药开发。获得此认定后，企业将能在研发过程中获得更密切的沟通与指导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","IE00BZ08YR35.GBP","01177","BK1515","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1521","BK1191","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.1948},{"period":"3month","weight":-0.0571},{"period":"6month","weight":-0.2506},{"period":"1year","weight":-0.2853},{"period":"ytd","weight":-0.1669}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.1164},{"period":"3month","weight":-0.0307},{"period":"6month","weight":-0.095},{"period":"1year","weight":-0.0098},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.007657},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056403},{"month":3,"riseRate":0.565217,"avgChangeRate":0.046203},{"month":4,"riseRate":0.478261,"avgChangeRate":0.020807},{"month":5,"riseRate":0.695652,"avgChangeRate":0.037978},{"month":6,"riseRate":0.347826,"avgChangeRate":0.004739},{"month":7,"riseRate":0.652174,"avgChangeRate":0.052934},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010627},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.014397},{"month":10,"riseRate":0.545455,"avgChangeRate":0.024699},{"month":11,"riseRate":0.5,"avgChangeRate":0.067223},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.012172}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}